Articles

In this first installment, Shubham Pant, MD, along with Tanios Bekaii-Saab, MD, discuss how patients are evaluated for pancreatic cancer. Read More ›

Lung cancer is the top cause of cancer death and the third most common cancer type in the United States, according to the National Cancer Institute. With an estimated 234,580 new cases of lung and bronchus cancer to be diagnosed in 2024 alone, this cancer will almost certainly affect a portion of your patients. Test your knowledge of this disease here. Read More ›

Breast cancer is the second most common cancer among women after skin cancer, according to the National Cancer Institute. In fact, in 2024 an estimated 310,720 cases will be diagnosed in women, representing 15.5% of all new cancers diagnosed that year, and 42,250 women with breast cancer will die. Test your knowledge of this widespread cancer. Read More ›

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses updated data from the phase 1a/1b trial of zongertinib in patients with HER2 aberration-positive solid tumors. In this video, she reports data from phase 1b, the ongoing dose expansion phase, which includes patients with HER2 mutation–positive NSCLC and focuses on nursing considerations for managing adverse events. Read More ›

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses the trial design of Beamion LUNG-2, a randomized phase 3 trial of zongertinib versus standard of care in patients with locally advanced or metastatic NSCLC harboring HER2 tyrosine kinase domain (TKD) mutations. She discusses the role of nurses in clinical trials, including providing essential monitoring and support to patients during their trial participation. Read More ›

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP, discusses results from an exposure-efficacy and exposure-safety analysis of trastuzumab deruxtecan in patients with HER2-mutated NSCLC. In her recap, she highlights the importance of education around dose adjustments to manage patient expectations. Read More ›